In order to investigate metabolic requirements of cells that evade chemotherapy-induced senescence, we treated with sublethal concentrations of doxorubicin two wild-type p53-positive cancer cell line, MCF-7 (breast adenocarcinoma) and A549 (lung adenocarcinoma). Here, TP53 is linked to lung adenocarcinoma.